Averion Plans to Go Private

Tuesday, September 8, 2009

Averion, a contract research organization (CRO) specializing in oncology, cardiovascular diseases and medical devices, has filed a statement with the Securities and Exchange Commission (SEC) as it plans to go from a publicly traded company to one that is private.

[Read More]

CT Approvals Down, Global Participation Up in Russia Q2

Wednesday, September 2, 2009

According to an Orange Paper released by Russia-based CRO, Synergy Research Group, Russia’s health agency, the Federal Service on Surveillance in Healthcare and Social Development (RosZdraNadzor, RZN) approved only 129 new clinical trials, including local and bioequivalence studies, during Q2 2009, representing a 17% decrease from Q2 last year. The percentage of approved multinational clinical trials increased slightly, however, to 65% of the total during this time period.

[Read More]